You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.
In Genome Biology this week: improved reference genome for the Asian tiger mosquito Aedes albopictus, links between Ebola variants and outcomes, and more.
Ebola viruses passaged in bat renal cells appeared to be subject to RNA editing by host enzymes, while more adaptive mutations arose after passaging in a human kidney cell line.
Based on expression patterns in mouse strains with variable infection susceptibility, investigators came up with a signature that predicted Ebola virus response in West Africa patients.
In Cell this week: B cell responses in Ebola survivors, two mRNA anti-terminator proteins, and more.
Researchers trained a machine-learning model to predict animal reservoirs or insect vectors for dozens of "orphan" viruses with unknown natural sources.
In PNAS this week: population structure in Helicoverpa, AMP-activated protein kinase levels in nicotine-exposed mice, and more.
The researchers found that the expression of certain genes was better at helping them predict when Ebola would develop than indications of infection like fever.
The Fraunhofer USA team will partner with a Fraunhofer Society institute in Germany in order to reduce the cost for its patented microchip that detects viruses including Ebola.
In PLOS this week: approach to diagnose hemorrhagic fevers, recessive disease mutations in mixed-breed dogs, and more.
An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.
The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.
CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.
In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.